Clinical Trials Logo

Filter by:
NCT ID: NCT04032717 Terminated - HIV Prevention Clinical Trials

Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)

PREVENT
Start date: July 10, 2019
Phase: Phase 1
Study type: Interventional

This is the first-in-human clinical study to see if a single dose of an investigational enema made from a modified plant protein called Q-Griffithsin is safe, tolerated, and acceptable for use by healthy adults 18-45 years of age who practice receptive anal intercourse.

NCT ID: NCT04032704 Terminated - Prostate Cancer Clinical Trials

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Start date: October 9, 2019
Phase: Phase 2
Study type: Interventional

This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

NCT ID: NCT04032444 Terminated - Orthopedics Clinical Trials

Collecting Orthopedic Safety and Performance Data Using Surgeons Clinical Outcomes Registry (SCOR)

SCOR
Start date: July 30, 2019
Phase:
Study type: Observational [Patient Registry]

The Surgeons Clinical Outcomes Registry (SCOR) is a global registry designed to collect safety and performance data on commercially available Wright Medical products. Registry data may be used for publications, education and marketing materials, post-market surveillance, future regulatory submissions, research and development for product design, software improvements, and development of artificial intelligence learning and tools.

NCT ID: NCT04032171 Terminated - Clinical trials for Relapsing-remitting Multiple Sclerosis

Study of Evobrutinib in Participants With RMS

Start date: September 10, 2019
Phase: Phase 3
Study type: Interventional

The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with Relapsing Multiple Sclerosis (RMS).

NCT ID: NCT04032158 Terminated - Clinical trials for Relapsing-remitting Multiple Sclerosis

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Start date: August 26, 2019
Phase: Phase 3
Study type: Interventional

The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with RMS.

NCT ID: NCT04031885 Terminated - Clinical trials for Metastatic Breast Cancer

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Start date: August 14, 2019
Phase: Phase 4
Study type: Interventional

The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to internal organs. Your participation in this trial could last up to 31 months, depending on your cancer type and how you and your tumor respond.

NCT ID: NCT04031404 Terminated - Clinical trials for Glucose Metabolism Disorders

Glucose and Non-Invasive Brain Stimulation

Start date: September 11, 2019
Phase: N/A
Study type: Interventional

Purpose: In this study, the investigators will delineate how brain network dynamics are modulated by experimentally induced elevated blood glucose levels and examine how glucose levels gate neuronal excitability measured by the response to TMS. Participants: Participants must be between the ages of 18 and 65 with no known diabetes, no known adverse reaction to finger prick blood draw, and no known neurological or psychiatric illness. Participants must have a body-mass index less than 30. Procedures: Participants will consume either a drink that contains 75 g of glucose or a placebo, and their response to TMS will be measured to examine the effect of glucose on motor cortex excitability.

NCT ID: NCT04030871 Terminated - Clinical trials for Long Term Enteral Tube Feeding

A Randomized, Pilot Study Comparing Cost Effectiveness on Two Commercially Available Gastric Feeding Tubes

Start date: October 25, 2019
Phase: N/A
Study type: Interventional

This document is a protocol for a human research study. This study is to be conducted according to US and international standards of Good Clinical Practice (International Conference on Harmonization ICHE6, R2), the Code of Federal Regulations Title 21 parts 803 and 812, and other applicable government regulations and Institutional research policies and procedures. The purpose of the study is to compare the cost effectiveness and tolerability of standard of care gastrostomy tubes to newer capsule dome gastrostomy tubes. The newer tubes are significantly more expensive, therefore the aims of this study will be to determine economic feasibility of going to the new model. Data are lacking on the newer g-tubes in terms of longevity and cost-effectiveness

NCT ID: NCT04030572 Terminated - Cancer Clinical Trials

Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies

a2a Agonist
Start date: December 10, 2019
Phase: Early Phase 1
Study type: Interventional

This will be a Phase 1, open label study of the pharmacokinetics (PK) and pharmacodynamics (PD) of clonidine, an alpha-2 adrenergic (a2a) agonist, in healthy volunteers. The primary aim is to show that the drug regimen is safe and reasonably well tolerated. The secondary aim is to demonstrate that safety can be monitored with home health devices.

NCT ID: NCT04030377 Terminated - Urinary Retention Clinical Trials

Postop Catheterization for Urinary Retention

Start date: April 2010
Phase:
Study type: Observational

This study investigates patient's preference and satisfaction with choice of catheterization after surgical urogynecological procedures.